未登录

S

Sheikh Mohammad Fazle Akbar

Ehime University Graduate School of Medicine

H指数:20

被引数:1,543

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nucleos(t)ide Analog–Therapeutic Vaccination Switch: A Novel Approach for Safe and Effective Treatment Discontinuation in HBeAg (-) Chronic Hepatitis B Patients

核苷(酸)类似物–治疗性疫苗接种转换：一种用于HBeAg阴性慢性乙型肝炎患者安全有效治疗终止的新方法

IF3.4

2026-09-190

OA

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders

IF3.4

2023-09-123

OAAI

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection

IF3.9

2023-07-082

OAAI

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon

IF3.4

2023-05-092

OAAI

Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines

对SARS-CoV-2的致病性和保护性免疫应答的细胞和分子机制以及新型冠状病毒肺炎疫苗的意义

IF3.4

2023-03-082

OAAI

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment

FRONTIERS IN MEDICINE

IF3

2023-02-085

OAAI

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B

IF3.4

2022-12-076

OAAI

Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection

IF3.4

2022-09-304

OAAI

Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling

LANCET REGIONAL HEALTH - SOUTHEAST ASIA

IF6.2

2022-09-014

OAAI

Immune therapies against chronic hepatitis B

JOURNAL OF GASTROENTEROLOGY

IF5.5

2022-06-1610

OAAI

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside

IF3.4

2022-05-101

OAAI

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial

IF3.4

2021-12-3018

OAAI

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

IF3.3

2021-11-0519

OAAI

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia

东南亚出生剂量疫苗接种对乙型肝炎病毒的影响

IF3.4

2021-04-1210

OAAI

Reply to Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19

ARCHIVOS DE BRONCONEUMOLOGIA

IF9.2

2021-04-011

OAAI

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19

ARCHIVOS DE BRONCONEUMOLOGIA

IF9.2

2020-12-0135

OAAI

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

亚太地区的肝脏疾病: 柳叶刀胃肠病学和肝病学委员会

LANCET GASTROENTEROLOGY & HEPATOLOGY

IF38.6

2020-02-01380

OAAI

High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank

SCIENTIFIC REPORTS

IF3.9

2019-08-219

OAAI

Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa

CLINICAL INFECTIOUS DISEASES

IF7.3

2019-05-1730

OAAI

HeberNasvac: Novel therapeutic vaccine against chronic hepatitis B

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI